New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
|Articles|April 1, 2010
- BioPharm International-04-01-2010
- Volume 23
- Issue 4
BioPharm International, April 2010 Issue (PDF)
A Better Way to Study Leachables from Container Closures
Advertisement
Articles in this issue
over 16 years ago
Preparing For an Uncertain Futureover 16 years ago
Biotech on a Roll to Start 2010over 16 years ago
Better Times Ahead for Biotechover 16 years ago
REMS Raise Concerns for Biotech ProductsAdvertisement
Related to this article
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Advertisement
Advertisement